• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effectiveness and safety of antiplatelet in stroke patients with end‐stage renal disease undergoing dialysis
ConclusionsAntiplatelet therapy, especially aspirin, still offers safe and effective treatment for ischemic stroke prevention in patients with end‐stage renal disease undergoing dialysis.
Source: International Journal of Stroke - February 1, 2014 Category: Neurology Authors: Chung‐Yu Chen, Kun‐Tai Lee, Charles Tzu‐Chi Lee, Wen‐Ter Lai, Yaw‐Bin Huang Tags: Research Source Type: research

Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke
ConclusionsThis real-world study suggests that cilostazol is effective and safe for noncardioembolic ischemic stroke and may be associated with better effectiveness in hypertensive patients compared to clopidogrel.
Source: European Journal of Clinical Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research

Comparison of Antiplatelet and Antithrombotic Therapy for Secondary Prevention of Ischemic Stroke in Patients With Peripheral Artery Disease.
Conclusions: Cilostazol and clopidogrel were more effective in preventing recurrent ischemic stroke without increased hemorrhagic events than aspirin in patients with PAD. PMID: 23269006 [PubMed - as supplied by publisher]
Source: Circulation Journal - December 26, 2012 Category: Cardiology Authors: Lee WH, Chu CY, Hsu PC, Su HM, Lin TH, Voon WC, Lai WT, Sheu SH Tags: Circ J Source Type: research

Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study
Conclusions Among patients with an ischaemic stroke while taking aspirin, clopidogrel initiation was associated with fewer recurrent vascular events than aspirin reinitiation.
Source: BMJ Open - December 2, 2014 Category: Journals (General) Authors: Lee, M., Wu, Y.-L., Saver, J. L., Lee, H.-C., Lee, J.-D., Chang, K.-C., Wu, C.-Y., Lee, T.-H., Wang, H.-H., Rao, N. M., Ovbiagele, B. Tags: Open access, Cardiovascular medicine, Epidemiology, Neurology Research Source Type: research

Efficacy and Safety of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Myocardial Infarction: A Nationwide Cohort Study.
This study aimed to compare the efficacy and safety of ticagrelor versus clopidogrel in East Asian patients with AMI. Between July 2013 and December 2015, patients with AMI prescribed with dual antiplatelet therapy were identified from the National Health Insurance Research Database of Taiwan. Using propensity score weighting, ticagrelor was compared with clopidogrel for the primary efficacy endpoint (a composite of all-cause death, MI, and stroke) and bleeding. A total of 32,442 patients with AMI (ticagrelor: 10,057; clopidogrel: 22,385) were eligible for analysis. After propensity score weighting, ticagrelor was comparab...
Source: Clinical Pharmacology and Therapeutics - August 6, 2020 Category: Drugs & Pharmacology Authors: Chang CJ, Tung YC, Liu JR, Chang SH, Kuo CT, See LC Tags: Clin Pharmacol Ther Source Type: research

One-year clinical outcomes of ticagrelor compared with clopidogrel after percutaneous coronary intervention in patients with acute myocardial infarction: From Korean Health Insurance Review and Assessment Data.
CONCLUSIONS: Among patients aged younger than 75 years, ticagrelor was associated with lower incidence of all-cause mortality. Stroke risk was also reduced in patients with a prescription for ticagrelor without an increase in bleeding risk. PMID: 30770037 [PubMed - in process]
Source: Journal of Cardiology - February 17, 2019 Category: Cardiology Authors: Kim C, Shin DH, Hong SJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Hong MK, Park J, Lee H, Kim DS, Oh SK, Jang Y Tags: J Cardiol Source Type: research

Millions of adults skip medications due to their high cost
Medications can do wonderful things, from fighting infection to preventing stroke and warding off depression. But medications don’t work if they aren’t taken. Some people don’t take their medications as prescribed because they forget, or are bothered by side effects. A new report from the National Center for Health Statistics shines the light on another reason: some people can’t pay for their medications. The survey, by NCHS researchers Robin A. Cohen and Maria A. Villarroel, found that about 8% of adult Americans don’t take their medicines as prescribed because they can’t afford them. I...
Source: New Harvard Health Information - January 30, 2015 Category: Consumer Health News Authors: Howard LeWine, M.D. Tags: Drugs and Supplements medication costs Source Type: news

Risk of Subarachnoid Hemorrhage and Early Case Fatality Associated With Outpatient Antithrombotic Drug Use Clinical Sciences
Conclusions— Outpatient antithrombotic drug use was associated with an increased risk of SAH, but no association was observed with early case fatality.
Source: Stroke - August 26, 2013 Category: Neurology Authors: Garbe, E., Kreisel, S. H., Behr, S. Tags: Heparin, Coumarins, Platelet function inhibitors, Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage Clinical Sciences Source Type: research

The risk of lower gastrointestinal bleeding in low ‐dose aspirin users
ConclusionsThe risk of LGIB was higher in low‐dose aspirin users than in aspirin nonusers in this nationwide cohort. Low‐dose aspirin, NSAIDs, steroids, SSRIs, PPIs and H2RAs were independent risk factors for LGIB.
Source: Alimentary Pharmacology and Therapeutics - April 27, 2017 Category: Drugs & Pharmacology Authors: W. ‐C. Chen, K.‐H. Lin, Y.‐T. Huang, T.‐J. Tsai, W.‐C. Sun, S.‐K. Chuah, D.‐C. Wu, P.‐I. Hsu Tags: Original Article Source Type: research

The Use Pattern and Clinical Impact of New Antiplatelet Agents Including Prasugrel and Ticagrelor on 30-day Outcomes after Acute Myocardial Infarction in Korea: Korean Health Insurance Review and Assessment Data.
CONCLUSION: The use of new antiplatelet agents is rapidly increasing, and they have been used more commonly than clopidogrel since 2015. We demonstrated that new antiplatelet agents have a favorable effect on reducing 30-day mortality in AMI patients in Korea. PMID: 29035430 [PubMed - as supplied by publisher]
Source: Korean Circulation Journal - October 18, 2017 Category: Cardiology Tags: Korean Circ J Source Type: research

Cardiovascular and Bleeding Risks in Acute Myocardial Infarction Newly Treated With Ticagrelor vs. Clopidogrel in Taiwan.
CONCLUSIONS: In real-world AMI Taiwanese patients, ticagrelor seemed to offer better anti-ischemic protection than clopidogrel, without an increase in the rate of major bleeding. A large-scale randomized trial is needed to assess the efficacy and safety of ticagrelor in East Asian AMI patients. PMID: 29081474 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 27, 2017 Category: Cardiology Authors: Lee CH, Cheng CL, Kao Yang YH, Chao TH, Chen JY, Li YH Tags: Circ J Source Type: research

Real-World Bleeding and Ischemic Events in Asian Patients on P2Y12-Inhibitors After Percutaneous Coronary Intervention: A National Claims Data Analysis
ConclusionsCDAPT was associated with clinical outcomes that were more favorable than those in TDAPT and comparable to those in PDAPT and drug persistence and adherence that were higher than in TDAPT or PDAPT. Clopidogrel may remain a viable first option for post-PCI DAPT in East Asian patients with a low thrombotic risk and a high bleeding tendency.
Source: Advances in Therapy - November 11, 2020 Category: Drugs & Pharmacology Source Type: research

Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease
Conclusion: In patients with an increased probability of non-persistence, an increased attention should be paid to improvement of persistence.
Source: Frontiers in Pharmacology - May 19, 2021 Category: Drugs & Pharmacology Source Type: research